Allergic asthma poses a significant global health challenge, with prevalence rates stabilizing in high-income countries but rising in low- and middle-income nations due to environmental and socioeconomic factors. This condition is characterized by airway hyperresponsiveness, dyspnea, coughing, and chest tightness, often accompanied by comorbidities like allergic rhinitis and atopic dermatitis, leading to worsened disease severity and reduced quality of life for patients.
The gut–lung axis has emerged as a critical framework for understanding the heterogeneity of allergic asthma. The gut microbiota, consisting of over 10¹⁴ microorganisms, plays a vital role in maintaining host homeostasis through various functions such as nutrient processing and barrier protection. Imbalances in the gut microbiota have been linked to immune dysregulation in allergic asthma, impacting T-cell fate decisions and exacerbating type-2 inflammation, which can weaken antiviral defenses and increase the risk of disease exacerbations.
Research has highlighted the role of microbial metabolites like short-chain fatty acids and tryptophan derivatives in modulating immune responses in allergic asthma. These metabolites interact with G-protein-coupled receptors to promote the differentiation of regulatory T cells and temper inflammation. Furthermore, dysbiosis in the gut microbiota can lead to downstream effects in the airways, such as oxidative stress, barrier dysfunction, and altered antigen presentation, contributing to disease pathogenesis.
Intervention strategies targeting the gut microbiota show promise in restoring microbial balance and reducing symptom burden in allergic asthma. Probiotics, prebiotics, synbiotics, postbiotics, and personalized dietary patterns have demonstrated early efficacy in rebalancing immune responses and restoring metabolite profiles. Future research directions aim to establish causal relationships between gut microbiota composition and allergic asthma through gnotobiotic and human challenge models, as well as large-scale randomized trials to validate intervention efficacy and safety.
Despite the progress in understanding the role of gut microbiota in allergic asthma, challenges remain, including the need for longitudinal studies with diverse endpoints and the consideration of individual factors like genetics and environment in personalized treatment approaches. By delineating the microbiota’s dual role as a biomarker and therapeutic target in allergic asthma, there is potential to advance towards preventive and personalized care strategies that offer long-term disease control with minimal side effects.
- The gut microbiota plays a crucial role in immune dysregulation in allergic asthma, impacting T-cell responses and inflammation.
- Interventions targeting the gut microbiota, such as probiotics and personalized dietary patterns, show promise in reducing symptom burden and restoring immune balance.
- Future research directions include establishing causal relationships through human challenge models and conducting rigorous randomized trials to validate intervention efficacy.
- Understanding the microbiota’s dual role as a biomarker and modifiable driver in allergic asthma opens avenues for preventive and personalized care strategies.
Tags: prebiotics, downstream, synbiotics, regulatory, microbiome, probiotics
Read more on emjreviews.com